ISMRM25 - Harnessing MSK MRI for Clinical Trials

ISMRM & ISMRT Annual Meeting & Exhibition • 10-15 May 2025 • Honolulu, Hawai'i

Harnessing MSK MRI for Clinical Trials

Weekday Course

ORGANIZERS: Alissa Burge, Hermien Kan, Jamie MacKay

Tuesday, 13 May 2025

320

15:45 - 17:45

Moderators: Chih-Liang Chin & Melissa Hooijmans

Skill Level: Intermediate

Session Number: Tu-03

CE Credit

Session Number: Tu-03

Overview
In this session, we will offer an overview of how MRI contributes to drug development, specifically in the musculoskeletal field. The event will commence with a broad look at imaging's role in clinical trials. Subsequently, two talks will delve into real-life applications of MRI in clinical trials for neuromuscular disease and arthritis. Finally, we will address the regulatory considerations surrounding the use of imaging endpoints.

Target Audience
Anyone with an interest in how MSK MRI (and MRI in general) can be used to enhance clinical trial design and delivery.

Educational Objectives
As a result of attending this course, participants should be able to:
• Recall the general roles that imaging can play in drug development;
• Explain specific applications of MSK MRI in clinical trials for neuromuscular disease and arthritis; and
• Describe the regulatory landscape governing the use of imaging endpoints in clinical trials.

15:45		Imaging in Drug Development 101 View Presentation Video Thomas Fuerst Impact: Imaging biomarkers play an increasingly important role in drug development, helping to ensure the safety and efficacy of new therapies and medical devices. Over the last three decades best practices for the use of imaging in clinical trials have emerged, which will be reviewed in this talk.
16:15		Regulatory Considerations for Use of Imaging Endpoints Christopher von Jako Impact: Real-world examples from recent and ongoing pharmaceutical collaborations highlight Xenon MRI’s utility in drug development for respiratory diseases.
16:45		MRI in Clinical Trials in Neuromuscular Disease View Presentation Video Rebecca Willcocks Impact: MR biomarkers such as muscle fat fraction have substantially impacted therapeutic development for muscular dystrophy. The presentation will provide an overview of evidence supporting the use of MR biomarkers, and describe the implementation of quantitative MR in clinical trials.
17:15		MRI in Clinical Trials in Joint Disease John Waterton